Tag: Impax Laboratories

  • Drug Stocks In News: Horizon Pharma (NASDAQ:HZNP), Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Impax Laboratories (NASDAQ:IPXL), KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)

    Horizon Pharma Inc., (NASDAQ:HZNP), a commercial stage company that markets two gastroprotective nonsteroidal anti-inflammatory drugs (NSAIDs), Vimovo and Duexis, announced that the FDA joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee was split on whether the data show adequate differences in cardiovascular risk among NSAIDs to support labeling change for NSAIDs due to cardiovascular risk. Horizon Pharma Inc (NASDAQ:HZNP) stock opened at $10.37 in last session, and closed at $10.86, while the day range of HZNP stock is $10.14 – $11.08. The stock showed a positive weekly performance of 8.17%.

    Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. Currently there are 5 analysts that rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) stock opened at $353.89, in last session and closed at $364.77, by gaining 5.27%. The 52 week range of ICPT is $30.38 – $497.00. Company’s market capitalization is $7.05billion.

    Impax Laboratories, Inc. (NASDAQ:IPXL) announced that the Company will release its fourth quarter and full year 2013 financial results on Thursday, February 20, 2014, after the close of the U.S. financial markets. Impax Laboratories Inc (NASDAQ:IPXL) stock advanced 5.35% and finished the last session at $23.82. The EPS of the stock remained 1.69. Company’s market capitalization is $1.66billion.

    KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company’s anti-EphA3 Humaneered® monoclonal antibody (mAb). KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) stock opened the session at $3.00, and closed the session at $3.15. The 52 week range of the KBIO stock remained $2.56 – $7.57 and the day range was $2.96 – $3.18.